Search for: "Bristol Myers Squibb Manufacturing Company"
Results 81 - 100
of 162
Sorted by Relevance
|
Sort by Date
20 Sep 2017, 9:18 am
In Bristol-Myers Squibb Co. v. [read post]
28 Aug 2018, 12:16 am
Although fact-specific, this case sets a threshold as to actions which would not constitute the repackaging of products (whilst Bristol-Myers Squibb and Boehringer Ingelheim set out actions which would). [read post]
12 Sep 2019, 5:44 pm
Francis Rooney (R-FL) wrote a letter to the FTC, urging the agency to investigate Bristol-Myers Squibb Company’s (“Bristol-Myers”) acquisition of Celgene Corporation (“Celgene”). [read post]
11 Jan 2022, 11:45 am
Bristol-Myers Squibb is not the first manufacturer to run into issues with the program. [read post]
11 Jan 2022, 11:45 am
Bristol-Myers Squibb is not the first manufacturer to run into issues with the program. [read post]
19 Jun 2014, 8:11 am
TAP Pharmaceuticals (Bristol Myers Squibb Appeal), No. 85 MAP 2011, slip op. [read post]
12 Jun 2013, 12:50 pm
The concerns relate to a number of widely prescribed GLP-1–based therapies, the 2 injectable GLP-1 agonists, exenatide (Byetta, Amylin/Lilly) and liraglutide (Victoza, Novo Nordisk), and the oral DPP-4 inhibitors sitagliptin, saxagliptin (Ongylza, AstraZeneca/Bristol-Myers Squibb), and linagliptin (Tradjenta, Boehringer Ingelheim/Lilly). [read post]
14 Feb 2017, 8:05 am
For this reason, sales of Eliquis, manufactured by Bristol Myers Squibb, are beginning to approach the numbers of Xarelto sales. [read post]
8 Aug 2014, 5:00 am
In Bristol-Myers Squibb Co. v. [read post]
12 Mar 2010, 4:06 pm
Source:http://www.webmd.com/heart-disease/news/20100312/new-plavix-warning-lack-of-effect-in-gene-carriersAs far back as November 23, 1998 the Federal Drug Administration (FDA) expressed its concern with the claims made by the drug manufacturer, Bristol-Myers Squibb/Sanofi Pharmaceuticals about Plavix. [read post]
2 Nov 2015, 7:42 am
Its joint manufacturers, Pfizer and Bristol-Myers Squibb, have recently kicked off a targeted direct-to-consumer advertising campaign to market the drug for a-fib treatment as well as for newly approved uses. [read post]
21 Apr 2016, 7:35 am
The first application pertained to Bristol-Myers Squibb’s cancer drug, Dastanib, which was filed by Indian generic drug manufacturer, BDR Pharma. [read post]
16 Sep 2016, 4:07 am
Previously, the Full Court in Bristol-Myers Squibb Company v Apotex Pty Ltd [2015] FCAFC 2 (BMS) upheld Justice Yates’ ruling at first instance that the grant of an ‘exclusive licence’ meant an exclusive licence to undertake all of the activities within the meaning of “exploit” as defined in the Patents Act. [read post]
28 Mar 2008, 7:25 am
Proponents have withdrawn resolutions at Abbott Laboratories, Aetna, Bristol-Myers Squibb, Eli Lilly, General Electric, IBM, Johnson & Johnson, McDonald's, Medco, WellPoint, ExxonMobil, Merck, Target, and Waste Management after many of the companies agreed to post statements on health care reform on their Web sites. [read post]
3 Apr 2023, 6:00 am
The Court’s ruling clarified its decisions in Bristol-Myers Squibb Co. v. [read post]
15 Jan 2009, 3:35 am
Just to recap then, the High Court of Delhi recently granted an ex parte restraining order in favour of Bristol Myers Squibb restraining the defendants, Hetero Drugs (an Indian generic firm) from manufacturing, selling, distributing, advertising, exporting, offering for sale or in any manner dealing directly or indirectly in any product infringing the plaintiffs product patent covering Dasatinib, a drug used in the treatment of Chronic Myloeid Leukemia. [read post]
17 Feb 2017, 12:21 pm
Bristol-Myers Squibb Co. v. [read post]
29 Jul 2013, 2:24 am
Unfortunately,without any thumbs, he was unable to forwardthem to the true recipient, Bristol-Myers Squibb When the parties engaged in correspondence, Teva refused to divulge its launch plans as it considered these plans confidential. [read post]
28 Nov 2016, 3:52 am
Abilify’s History Approved by the FDA in 2002, Abilify, which comes in many forms, including a tablet, liquid or an injection (including an extended-release injection), is manufactured by Bristol-Myers Squibb and the Otsuka America Pharmaceutical, and has consistently topped 5 billion dollars in yearly sales. [read post]
8 Mar 2012, 3:34 am
Those competitors included AstraZeneca, Merck & Co., Bristol-Myers Squibb Co., GlaxoSmithKline PLC and others that have disclosed investigations for possible FCPA breaches. [read post]
